Brought to you by 
Molecular Biosystems licenses contrast agents to Chugai
28 May 2013
Executive Summary
Molecular Biosystems exclusively licensed to Chugai Pharmaceuticals its FS069 and Oralex for development and sale in Japan, Taiwan, and South Korea.
Deal Industry
- Biotechnology
- In Vitro Diagnostics
- Pharmaceuticals
-
Pharmaceuticals
- Radiopharmaceuticals, Contrast Agents
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Molecular Biosystems licenses contrast agents to Chugai
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice